Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936715 · ClinicalTrials.gov registry record · Phase 2
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00936715 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 24 participants.
The verdict
NCT00936715, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to provide open label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study GS-US-203-0107.
Interventions
- DRUG FTC/TDF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936715
The ClinicalTrials.gov registry entry for NCT00936715 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FTC/TDF is the first listed.
NCT00936715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936715 about?
NCT00936715 is a clinical study titled "Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States". The objective of this study is to provide open label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for an additional 5 years (240 weeks) to adults completing study GS-US-203-0107.
What is the current status of trial NCT00936715?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00936715?
The interventions under investigation include: FTC/TDF (DRUG).
Who is sponsoring clinical trial NCT00936715?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.